Naglazyme After Allo Transplant for Maroteaux-Lamy Syndrome
Status:
Terminated
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This is a single center study in which Naglazyme® will be given weekly for two years in
patients with Maroteaux-Lamy syndrome, also known as mucopolysaccharide VI (MPS VI), who have
previously been treated with an allogeneic transplant.